HPV DNA Integration Pattern Classification via In Situ Hybridization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing HPV DNA integration patterns in cervical cancer tissues are inaccurate in distinguishing between episomal and multicopy tandem-repetition integrated forms, particularly in advanced stages of cervical cancer, limiting their ability to predict prognosis and tailor treatment effectively.
Innovation Solution
The method involves using in situ hybridization (ISH) to observe and classify HPV DNA integration patterns into episomal, single-copy integration, multicopy tandem-repetition, and non-observed patterns, allowing for more accurate prognosis analysis and individualized treatment approaches based on these classifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR method is used to detect HPV DNA integration patterns, then the presence of episomal or integrated HPV can be detected, but the method cannot accurately distinguish between different integration patterns (single-copy vs multicopy tandem-repetition) particularly in advanced cervical cancer stages
Solution Approach 1:
The patent segments the detection process into multiple stages: initial HPV detection, followed by classification into specific integration patterns (episomal, single-copy integrated, multicopy tandem-repetition integrated). This segmentation allows each pattern type to be identified with specific methodologies, improving overall detection precision for different cervical cancer stages
Solution Approach 2:
The patent introduces a new dimension of analysis by classifying HPV DNA not just as present/absent but by specific integration patterns (episomal, single-copy, multicopy tandem-repetition). This dimensional classification enables differentiation of integration patterns that traditional PCR cannot distinguish, particularly in advanced cervical cancer stages
2Productivity
If uniform therapy is applied to all cervical cancer patients, then treatment simplicity is maintained, but the complete cure rate and quality of life cannot be optimized for different risk groups
Solution Approach 1:
The patent applies local quality by tailoring treatment protocols to specific HPV DNA integration patterns. Patients with episomal patterns receive different therapy (potentially less aggressive) compared to those with integrated patterns (requiring more aggressive treatment). This localized treatment approach optimizes cure rates while managing treatment complexity through clear classification criteria
Solution Approach 2:
The patent changes the treatment parameter based on HPV DNA integration pattern classification. By using the integration pattern as a biomarker, the treatment intensity and type are adjusted accordingly, enabling personalized medicine approaches that improve complete cure rates without unnecessarily complicating treatment for all patients
3Reliability
If high doses of radiation and anticancer agents are used to improve complete cure rate, then treatment effectiveness increases, but adverse effects and treatment complications increase
Solution Approach 1:
The patent applies partial action by recommending reduced radiation and anticancer agent doses for patients with episomal HPV patterns who have lower risk of progression, while reserving full-dose aggressive therapy for patients with integrated patterns who require higher treatment intensity. This differential approach maintains complete cure rates for high-risk patients while reducing harmful effects for low-risk patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise prediction of cervical cancer prognosis and treatment outcomes, improving survival rates and reducing treatment complications by tailoring radiation and anticancer agent use based on specific HPV DNA integration patterns.
Implementation Method 1
The method involves using in situ hybridization (ISH) to observe and classify HPV DNA integration patterns
Data Source
AI summary
Provided is a method for analyzing the prognosis of cervical cancer according to the human papillomavirus (HPV) DNA integration pattern. The method of analyzing the prognosis of cervical cancer according to the human papillomavirus DNA integration pattern of the present invention enables an observation of the HPV DNA integration pattern with accuracy and convenience via in situ hybridization (ISH) compared to qPCR analysis. Since the prognosis of cervical cancer having the tumors with an episomal pattern and an integrated pattern can be significantly distinguished when the HPV DNA integration patterns are classified by the above method, the survival rate after radiotherapy of cervical cancer, and in particular invasive cervical cancer, can be more accurately analyzed.